US2016317631A1PendingUtilityA1
Increased t-cell tumor infiltration and eradication of metastases by mutant light
Est. expiryJun 11, 2023(expired)· nominal 20-yr term from priority
Inventors:Yang-Xin Fu
A61K 2039/53A61P 37/04C07K 2319/43C12N 2710/10043A61K 2039/5256C12N 2799/022A61P 35/04C12N 7/00A61K 40/428A61K 40/32A61K 40/11A61K 39/0011A61K 2239/38C07K 14/525A61K 2039/5152
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.
Claims
exact text as granted — not AI-modified1 .- 39 . (canceled)
40 . A method of inducing tumor-specific T-cell generation to reduce or control metastasis, the method comprising:
(a) introducing a mutant LIGHT protein or a fragment thereof into an individual at a tumor site, wherein the mutant LIGHT protein or fragment does not have a proteolytic site; and (b) reducing or controlling metastasis by inducing T-cell generation.
41 . The method of claim 40 , wherein the generated T-cells are activated within a tumor site.
42 . The method of claim 40 , wherein the generated T-cells circulate in blood.
43 . The method of claim 42 , wherein the circulating T-cells are cancer specific.
44 . The method of claim 40 , wherein the mutant LIGHT protein or the fragment is introduced into a tumor cell in vitro and the tumor cell expressing the mutant LIGHT protein or the fragment is delivered to the individual.
45 . The method of claim 40 , wherein the T-cell generation is CD8+ dependent.Join the waitlist — get patent alerts
Track US2016317631A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.